

Filed on behalf of Petitioner COALITION FOR AFFORDABLE DRUGS II
LLC

By: Jeffrey D. Blake, Esq.
MERCHANT & GOULD P.C.
191 Peachtree Street N.E., Suite 4300
Atlanta, GA 30303
jblake@merchantgould.com
Main Telephone: (404) 954-5100
Main Facsimile: (404) 954-5099

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS II LLC
Petitioner

v.

NPS PHARMACEUTICALS, INC.
Patent Owner

Case No. To be assigned
Patent 7,056,886

**DECLARATION OF ANTHONY PALMIERI III, Ph.D., R.Ph.
FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 7,056,886
(CLAIMS 46-52 and 61-75) UNDER 35 U.S.C. §§ 311-319
AND 37 C.F.R. § 42.100 *et seq.***

TABLE OF CONTENTS

I. INTRODUCTION 1

II. QUALIFICATIONS 3

III. COMPENSATION, PRIOR TESTIMONY, AND RELATIONSHIP
TO THE PARTIES 5

IV. SUMMARY OF OPINION 5

V. LEGAL STANDARDS 7

 A. Claim Construction 8

 B. Obviousness 8

 C. A Person of Ordinary Skill in the Art 8

VI. CONCURRENT LITIGATION 9

VII. DETAILED OPINION 9

 A. Person of Ordinary Skill in the Art 9

 B. How the Challenged Claims Are to Be Construed 10

 C. Relevant Time Frame for Analysis of the '886 Patent 12

 D. Overview of the State of the Art Prior to December 29, 2000
 and the Cited Prior Art 13

 E. Cited Art Applied is Prior Art to the '886 Patent 15

 F. Claims 46-52 and 69-75 Are Unpatentable Because They
 Would Have Been Obvious Over Drucker '379 in view of

Declaration of Anthony Palmieri III, Ph.D.
Inter Partes Review of U.S. Patent No. 7,056,886

Kornfelt, Osterberg, and Munroe	16
1. Each of the Limitations of Claims 46-52 and 69-75 Are Found in Drucker '379, Kornfelt, Osterberg, and Munroe	16
a. Independent Claim 46.....	29
i. A GLP-2 Formulation was Known	30
ii. About 0.1 to About 50 mg/ml of A GLP-2 Peptide Or An Analog Thereof was Known	30
iii. A Phosphate Buffer In An Amount Sufficient to Adjust the pH Of The Formulation To A Pharmaceutically Tolerable Level was Known.....	32
iv. About 0.5 to About 1% L-histidine and About 2% to About 5% Mannitol Would Be Obvious to Use	34
b. Independent Claim 52.....	41
i. A GLP-2 Formulation was Known	42
ii. A Medically Useful Amount of a Naturally Occurring GLP-2 Peptide or an Analog Thereof was Known	42
iii. A Phosphate Buffer in an Amount Sufficient to Adjust the pH of the Formulation to a Physiologically Tolerable Level was Known	44
iv. L-Histidine in an Amount Sufficient to Stabilize the Formulation Would be Obvious to Use.....	46

Declaration of Anthony Palmieri III, Ph.D.
Inter Partes Review of U.S. Patent No. 7,056,886

v.	Using a Bulking Agent Selected from the Group Consisting of Mannitol and Sucrose is Obvious.....	48
c.	Independent Claim 69.....	53
i.	A Method for Treating a Human or Animal having a Gastrointestinal Disorder, Disease or Condition for Which Treatment with GLP-2 is Indicated Including Administering a Therapeutically Effective Amount of a GLP-2 Formulation was Known	54
ii.	A GLP-2 Peptide or an Analog Thereof was Known	57
iii.	A Phosphate Buffer in an Amount Sufficient to Adjust the pH of the Formulation to a Pharmaceutically Tolerable Level was Known	57
iv.	L-histidine Would be Obvious to Use.....	59
v.	A Bulking Agent Selected from the Group Consisting of Mannitol and Sucrose Would be Obvious to Use	60
vi.	Enhancing, Maintaining, or Promoting the Growth or Functioning of the Gastrointestinal Tract Was Known	62
d.	Claims 47-72.....	67
e.	Claim 48.....	67
f.	Claims 49 and 70	68
g.	Claims 50 and 71	69

iii

Declaration of Anthony Palmieri III, Ph.D.
Inter Partes Review of U.S. Patent No. 7,056,886

h.	Claims 51 and 75	69
i.	Claims 73 and 74	70
G.	Claims 61-68 Are Unpatentable Because They Would Have Been Obvious Over Drucker '600 in view of Kornfelt, Holthuis, Osterberg, and Munroe.....	71
1.	Each of the Limitations of Claims 61-68 Are Found in Drucker '600, Kornfelt, Osterberg, and Munroe.....	72
a.	Independent Claim 61	81
i.	A Kit Including a Lyophilized GLP-2 Formulation was Known	82
ii.	A GLP-2 Peptide or an Analog Thereof was Known	83
iii.	A Phosphate Buffer in an Amount Sufficient to Adjust the pH of the Formulation to a Pharmaceutically Acceptable Level was Known	83
iv.	L-histidine Would be Obvious to Use.....	85
v.	A Bulking Agent Selected from the Group Consisting of Mannitol and Sucrose Would be Obvious to Use	87
vi.	A Vial of Sterile Water for Reconstitution Would be Obvious to Use	88
vii.	Instructions Directing Reconstitution were Known, or Alternatively, Obvious to Use.....	89
b.	Claims 62 and 63	95

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.